We are live on ! Find out more
BLRX

BioLineRX
BLRX

28 hedge funds and large institutions have $40.9M invested in BioLineRX in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 28 → 28 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% less ownership

Funds ownership: 0.06% → 0.06% (-0%)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

6% less capital invested

Capital invested by funds: $43.4M → $40.9M (-$2.45M)

Holders
28
Holders Change
–
Holders Change %
0%
% of All Funds
0.64%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
7
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$181K
2
Morgan Stanley
Morgan Stanley
New York
+$153K
3
Millennium Management
Millennium Management
New York
+$95.5K
4
UBS Group
UBS Group
Switzerland
+$46.8K
5
JP Morgan Chase
JP Morgan Chase
New York
+$31.6K

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$1.7M
2
MCC
Malaga Cove Capital
California
-$51K
3
HIIFS
Harel Insurance Investments & Financial Services
Israel
-$47.4K
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$20K
5
Bank of America
Bank of America
North Carolina
-$18K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$28.3M – – –
SM
2
Senvest Management
New York
$8.48M – – –
Morgan Stanley
3
Morgan Stanley
New York
$1.14M +$153K +233 +15%
O
4
OrbiMed
New York
$1.13M – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$474K +$181K +275 +61%
Deutsche Bank
6
Deutsche Bank
Germany
$297K -$1.7M -2,573 -85%
OM
7
Opaleye Management
Massachusetts
$272K – – –
BCA
8
Benchmark Capital Advisors
New York
$156K -$3.29K -5 -2%
EMG
9
ETF Managers Group
New Jersey
$115K +$10.5K +16 +10%
Millennium Management
10
Millennium Management
New York
$95K +$95.5K +145 New
NFG
11
Next Financial Group
Texas
$74K – – –
Commonwealth Equity Services
12
Commonwealth Equity Services
Massachusetts
$60K – – –
UBS Group
13
UBS Group
Switzerland
$48K +$46.8K +71 +2,367%
HIIFS
14
Harel Insurance Investments & Financial Services
Israel
$43K -$47.4K -72 -52%
CCB
15
Cutter & Co Brokerage
Missouri
$39K +$5.27K +8 +15%
JP Morgan Chase
16
JP Morgan Chase
New York
$31K +$31.6K +48 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$27K – – –
VanEck Associates
18
VanEck Associates
New York
$25K -$17.8K -27 -42%
OAM
19
Oxford Asset Management
United Kingdom
$25K +$25K +38 New
Citadel Advisors
20
Citadel Advisors
Florida
$24K +$11.2K +17 +89%
AIC
21
Aurora Investment Counsel
Georgia
$16K +$15.8K +24 New
Creative Planning
22
Creative Planning
Kansas
$11K – – –
LTFS
23
Ladenburg Thalmann Financial Services
Florida
$9K +$4.61K +7 +88%
PVH
24
Psagot Value Holdings
Israel
$6K -$5.27K -8 -47%
CHP
25
Cable Hill Partners
Oregon
$3K – – –
1
2

BLRX Hedge Fund Activity: Q4 2017 in Review

28 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2017, worth a combined $40.9M — down 5.6% from $43.4M a quarter earlier.

Fund positioning in BLRX was balanced in Q4 2017: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 7 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $181K. The largest seller was Deutsche Bank, cutting an estimated $1.7M.

  • 28 institutional investors held BioLineRX (BLRX) as of Q4 2017, unchanged from Q3 2017.
  • Funds reported $40.9M of BioLineRX stock for Q4 2017, down 5.6% quarter-over-quarter.
  • 4 funds opened new BioLineRX positions in Q4 2017 and 4 closed out, a net change of 0 holders.
  • The largest BioLineRX buyer in Q4 2017 was Renaissance Technologies, an estimated $181K added.
  • The largest BioLineRX seller in Q4 2017 was Deutsche Bank, an estimated $1.7M sold.

Based on aggregated 13F filings for Q4 2017.